View in EDS HTML Full Text PDF Full Text

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

Saved in:
Bibliographic Details
Title: A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Authors: Chen HJ; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China., Tu HY; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China., Hu Y; Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China., Fan Y; Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China., Wu G; Department of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China., Cang S; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China., Yang Y; Department of Thoracic Surgery, The Third People's Hospital of Chengdu, Chengdu, China., Yang N; Department of Oncology, The Second People's Hospital of Hunan, Changsha, China., Ma R; Department of Thoracic Oncology, Liaoning Cancer Hospital & Institute, Shenyang, China., Jin G; Department of Medical Oncology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, China., Xu X; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China., Liu A; Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China., Tang S; Department of Oncology, The First People's Hospital of Neijiang, Neijiang, China., Cheng Y; Department of Oncology, Jilin Cancer Hospital, Changchun, China., Yu Y; Department of Thoracic Medicine, Harbin Medical University Cancer Hospital, Harbin, China., Xu CR; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China., Zhou Q; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China., Wu YL; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China. syylwu@live.cn.
Source: Journal of hematology & oncology [J Hematol Oncol] 2025 Jan 05; Vol. 18 (1), pp. 3. Date of Electronic Publication: 2025 Jan 05.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39757186
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chen+HJ%22">Chen HJ</searchLink>; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Tu+HY%22">Tu HY</searchLink>; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Hu+Y%22">Hu Y</searchLink>; Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Fan+Y%22">Fan Y</searchLink>; Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+G%22">Wu G</searchLink>; Department of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.<br /><searchLink fieldCode="AU" term="%22Cang+S%22">Cang S</searchLink>; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Department of Thoracic Surgery, The Third People's Hospital of Chengdu, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Yang+N%22">Yang N</searchLink>; Department of Oncology, The Second People's Hospital of Hunan, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Ma+R%22">Ma R</searchLink>; Department of Thoracic Oncology, Liaoning Cancer Hospital & Institute, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Jin+G%22">Jin G</searchLink>; Department of Medical Oncology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, China.<br /><searchLink fieldCode="AU" term="%22Xu+X%22">Xu X</searchLink>; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Liu+A%22">Liu A</searchLink>; Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.<br /><searchLink fieldCode="AU" term="%22Tang+S%22">Tang S</searchLink>; Department of Oncology, The First People's Hospital of Neijiang, Neijiang, China.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Department of Oncology, Jilin Cancer Hospital, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Yu+Y%22">Yu Y</searchLink>; Department of Thoracic Medicine, Harbin Medical University Cancer Hospital, Harbin, China.<br /><searchLink fieldCode="AU" term="%22Xu+CR%22">Xu CR</searchLink>; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+Q%22">Zhou Q</searchLink>; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+YL%22">Wu YL</searchLink>; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China. syylwu@live.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101468937%22">Journal of hematology & oncology</searchLink> [J Hematol Oncol] 2025 Jan 05; Vol. 18 (1), pp. 3. <i>Date of Electronic Publication: </i>2025 Jan 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Biomed+Central%22">Biomed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101468937 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1756-8722 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217568722%22">17568722 </searchLink><i>NLM ISO Abbreviation: </i>J Hematol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39757186
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13045-024-01656-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3
    Titles:
      – TitleFull: A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen HJ
      – PersonEntity:
          Name:
            NameFull: Tu HY
      – PersonEntity:
          Name:
            NameFull: Hu Y
      – PersonEntity:
          Name:
            NameFull: Fan Y
      – PersonEntity:
          Name:
            NameFull: Wu G
      – PersonEntity:
          Name:
            NameFull: Cang S
      – PersonEntity:
          Name:
            NameFull: Yang Y
      – PersonEntity:
          Name:
            NameFull: Yang N
      – PersonEntity:
          Name:
            NameFull: Ma R
      – PersonEntity:
          Name:
            NameFull: Jin G
      – PersonEntity:
          Name:
            NameFull: Xu X
      – PersonEntity:
          Name:
            NameFull: Liu A
      – PersonEntity:
          Name:
            NameFull: Tang S
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Yu Y
      – PersonEntity:
          Name:
            NameFull: Xu CR
      – PersonEntity:
          Name:
            NameFull: Zhou Q
      – PersonEntity:
          Name:
            NameFull: Wu YL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 01
              Text: 2025 Jan 05
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1756-8722
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of hematology & oncology
              Type: main
ResultId 1